NEW YORK, March 24, 2011 /PRNewswire/ — Reportlinker.com
announces that a new market research report is available in its
catalogue:
Therapeutics for Immune System Disorders
http://www.reportlinker.com/p0461662/Therapeutics-for-Immune-System-Disorders.html
In 2010, the global market for drugs for the treatment of immune
disease was estimated to be approximately $72.2 billion. The
market size is forecast to grow at a compound annual growth rate
(CAGR) of 2.6% to reach $82.2 billion by 2015.
The market size of immunomodulators in 2010 is estimated to be
$62.8 billion, accounting for 86.9% of the overall market. The
market for immunomodulators is expected to grow by a compound
annual growth rate (CAGR) of 3.4% to reach $74.1 billion by 2015,
accounting for 90.2% of the market.
The demand for symptom–treating drugs is declining as
advancements in immunology and life sciences help to target the
underlying causes of the diseases. The market size of symptom
treating diseases is expected to decline at a compound annual
growth rate (CAGR) of –3.1% from $9.4 billion in 2010 to $8.1
billion in 2015.
INTRODUCTION
STUDY GOAL AND OBJECTIVES
This in–depth study examines recent commercial
developments in immune disease treatments. There has been an
explosion in knowledge concerning the immune system, and tremendous
advancements in disease diagnosis and therapies with novel
approaches – predominantly biologic–based treatments
– replacing the traditional methods where emphasis was to
treat the symptoms in order to improve the quality of life of the
patient rather than treating
‘/>”/>
